Year: 2017
Type: article
Study design: Observational Study
Abstract: INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is a significant cause of morbidity in persons living with HIV (PLWH) and HIV appears to uniquely cause COPD, independent of smoking. The mechanisms by which HIV leads to COPD are not clear. The objective of this study was to identify metabolomic biomarkers and potential mechanistic pathways of HIV-associated COPD (HIV-COPD). METHODS: We performed case-control metabolite profiling via mass spectrometry in plasma from 38 individuals with HIV-COPD (cases), comparing to matched controls with/without HIV and with/without COPD. Untargeted metabolites of interest were identified with liquid chromatography with mass spectrometry (LC-MS/mass spectrometry (MS)), and targeted metabolomics for tryptophan (Trp) and kynurenine (Kyn) were measured by selective reaction monitoring (SRM) with LC-MS/MS. We used mixed-effects models to compare metabolite concentrations in cases compared with controls while controlling for relevant biological variables. RESULTS: We identified 1689 analytes associated with HIV-COPD at a false discovery rate (FDR) of 10%. In PLWH, we identified 263 analytes (10% FDR) between those with and without COPD. LC MS/MS identified Trp and 17 lipids, including sphingolipids and diacylglycerol. After adjusting for relevant covariates, the Kyn/Trp ratio measured by SRM was significantly higher in PLWH (p=0.022), but was not associated with COPD status (p=0.95). CONCLUSIONS: There is a unique metabolite profile in HIV-COPD that includes sphingolipids. Trp metabolism is increased in HIV, but does not appear to independently contribute to HIV-COPD. TRIAL REGISTRATION NUMBERS: NCT01810289, NCT01797367, NCT00608764.
Source: BMJ Open Respiratory Research
Institutions: University of Minnesota, Minneapolis VA Medical Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,085
Funders: U.S. Department of Veterans Affairs, Bristol-Myers Squibb, Pfizer, AstraZeneca, GlaxoSmithKline, Gilead Sciences, University of Minnesota, COPD Foundation, Sunovion, ViiV Healthcare, Janssen Scientific Affairs, National Institutes of Health, National Heart, Lung, and Blood Institute, National Institute of Allergy and Infectious Diseases
Awards: G1689438493, International Network for Strategic Initiatives in Global HIV Trials (INSIGHT): START, G2644038179, International Network for Strategic Initiatives in Global HIV Trials (INSIGHT), G377726100, Effects of HIV antiretroviral therapy on pulmonary function in a randomized trial, G489861760, G535525194, (2 of 2) Genetic Epidemiology of COPD, G6115781543, G9000033803, G9000081360
OpenAlex ID: W2604556111
